Agency in Dystonia

Neuronal Correlates of Agency in Dystonia

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03351218

Acronym

AGENT10

Enrollment

Registered

2017-11-22

Start date

2017-10-23

Completion date

2022-12-20

Last updated

2025-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dystonia, Primary

Brief summary

In this study, using computerized cognitive assessments combined with multi-modal neuroimaging approach investigators aim to address three specific questions on patients with cervical and myoclonus dystonia: (i) investigate various aspects of the sense of agency and relationship to the severity of dystonia symptoms, (ii) characterize the possible link between abnormalities of movement perception and alteration of sense of agency in dystonia, (iii) (identify the neuronal underpinnings of the defective sense of agency in dystonia.

Detailed description

This is a single-centre, two-group ( dystonia and control), case-control study using behavioural and novel multimodal neuroimaging techniques to address the study aims. The battery of the tasks will include explicit-agency tasks, a visual discrimination task on objects movement perception. The magnetic resonance acquisition protocol will include MP2RAGE structural (10 min duration), multi echo (3 echo times) multiband (MB factor 4) resting state functional neuroimaging (15 minutes duration) and multi shell diffusion imaging sequence (15 minutes duration)

Interventions

BEHAVIORALBehavioral testing - computerized tasks

Cognitive behavioral testing and cerebral MRI

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Intervention model description

Two groups study : patients versus healthy controls

Eligibility

Sex/Gender

ALL

Age

15 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* diagnosis of isolated adult-onset cervical dystonia (CD) or myoclonus dystonia (MD); * duration of disease of more than one year * no botulinum toxin injection for at least three months before the study * normal or corrected-to-normal vision.

Exclusion criteria

* any neurological history except for dystonia, * history of dopamine antagonist treatment, * secondary dystonia, * dystonia in the upper limbs, * inability to maintain gaze straight.

Design outcomes

Primary

Measure	Time frame	Description
agency tasks behavioral outcome measures	throughout study completion, an average 2 years	response time

Secondary

Measure	Time frame	Description
MRI measures	throughout study completion, an average 2 years	cortical thickness

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026